PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well 18F-DCFPyL positron emission tomography (PET)/magnetic
resonance imaging (MRI) works for the diagnosis of prostate cancer in men with a PSA greater
than or equal to 2 ng/mL. 18F-DCFPyl is a radioactive injectable imaging agent made of a
prostate specific membrane antigen (PSMA) that attaches to tumor cells, which makes it useful
for the diagnosis of prostate cancer. A PET scan is an imaging tool that may help find the
location of cancer, by using a radioactive drug and a computer to create images of how organs
and tissues in the body are functioning. A mp-MRI is used to help determine the extent of a
patient's cancer. A MRI scan uses strong magnets and computers to create detailed images of
the soft tissue in the body. This trial aims to compare PET scans to prostate specific mp-MRI
to evaluate prostate cancer severity in men with a positive screen for prostate cancer.